Subscription-focused twist, EPAM’s InfoNgen platform targets research-heavy clients

EPAM’s InfoNgen SaaS platform is designed to help banks, pharma groups and corporates filter thousands of news and research sources into actionable insights. The specialized subscription service underscores how EPAM pushes beyond custom projects into recurring cloud software revenue.

Edited by ad hoc news Software & Services Desk. Reviewed before publication on 06/15/2026 at 4:15 PM ET. Details in the imprint.

EPAM’s InfoNgen research-intelligence platform sits at the center of the company’s push into subscription software, targeting banks, life sciences firms and corporates that need to turn unstructured content into usable insight without building their own search stack from scratch. The cloud service ingests news, premium research, filings and internal documents, then applies machine learning and linguistic rules so users can surface only the material that matters to a given portfolio, product line or compliance mandate.

What EPAM’s InfoNgen platform is built to do

InfoNgen is positioned as a software-as-a-service layer on top of EPAM’s broader data and AI consulting work, providing a configurable search and alerting engine rather than a one-off custom solution. The platform is designed to index millions of documents from external sources such as news feeds, analyst research and regulatory filings, alongside internal PDFs, emails and knowledge bases, and then normalize this content into consistent entities like companies, products and themes so that knowledge workers can query it without dealing with raw document noise. According to EPAM’s own product materials, InfoNgen combines machine learning classifiers with rule-based text analytics to perform entity extraction, deduplication and sentiment tagging across the incoming streams, which helps corporate users reduce manual clipping and spreadsheet tracking. EPAM’s information intelligence overview describes InfoNgen as a SaaS platform for aggregating and classifying external and internal research content.

For front-office users in banking and asset management, the typical workflow centers on building saved searches and alerts that map directly to coverage lists or investment themes so that analysts receive updates on only the companies, sectors or regulatory topics they follow. These users can monitor earnings commentary, broker research summaries and key macro releases in a single interface instead of jumping between multiple terminals and email lists, which can matter for firms that are cost-conscious about traditional market-data terminals. On the pharmaceutical and life sciences side, InfoNgen is pitched at teams that track scientific publications, clinical-trial registries, health-authority guidance and competitive pipelines; the platform’s taxonomy and entity-recognition tools make it easier to follow a molecule, indication or trial phase across different publishers and document formats, reducing the risk that a critical update is missed because it appeared in an obscure journal or regulator bulletin rather than a mainstream newswire.

EPAM highlights that InfoNgen’s search layer is complemented by configurable dashboards and alerting mechanisms, allowing business users to create topic or watchlist pages that surface trending documents without having to know the underlying data schema. These dashboards can be organized by theme - for example, ESG controversies, supply-chain disruptions or specific therapeutic areas - and can be shared across teams so that a bank’s sector group or a drug maker’s therapeutic franchise has a common view of the latest material. In many deployments, the service is integrated into existing collaboration tools and intranet portals through APIs and widgets, so that end users see alerts and summaries within their day-to-day workflow rather than needing to log into a standalone website. For compliance and risk functions, the same infrastructure can be used to monitor regulatory communications or enforcement actions across jurisdictions, which is especially relevant to cross-border organizations looking to unify their view of fragmented oversight regimes.

From a technical perspective, InfoNgen is delivered as a multi-tenant cloud service, with EPAM handling scaling, source onboarding and ongoing model updates while clients focus on configuring topics and access controls. The company emphasizes that the platform supports complex Boolean queries and proximity operators, which matters for research professionals who routinely work with nuanced combinations of entities, time windows and event types. Many implementations rely on feeds from licensed content providers alongside public sources and internal documents, and EPAM typically configures connectors so that clients can maintain existing licensing arrangements rather than renegotiate content rights. Because the platform treats external and internal content similarly once it is ingested, firms can apply the same tagging and governance policies across both, reducing duplication of research and making it easier to audit who had access to which document and when.

EPAM’s own marketing describes InfoNgen as part of its "information intelligence" solution family that complements advisory and custom engineering projects, giving the firm something reusable to deploy across multiple clients instead of building bespoke search systems each time. That positioning aligns with the broader trend among IT services providers to cultivate recurring subscription revenue on top of project-based work, particularly when it comes to AI and data products that can be tuned for individual industries but share a common core. In regulated sectors such as financial services and healthcare, a pre-hardened platform that already supports complex permissioning, audit logs and data lineage can shorten deployment timelines compared with greenfield development.

Within EPAM’s portfolio, InfoNgen illustrates how the company tries to move up the value chain from pure staff-augmentation projects toward packaged platforms and domain solutions that can be replicated and maintained at scale. The company’s investor materials have pointed in recent years to data, analytics and AI as areas of strategic focus, and products such as InfoNgen give that narrative something concrete beyond consulting slideware. While EPAM does not break out revenue by individual product, offerings in this category can contribute to more predictable recurring revenue and deepen relationships with clients in capital markets, asset management and life sciences, all of which are industries where the company has a meaningful presence. EPAM Systems, Inc. shares (ISIN US29414B1044) trade on the New York Stock Exchange, and the stock recently changed hands at around the mid-$90 level, reflecting a market that is still recalibrating expectations after the broader reset in digital transformation spending; according to an exchange quote service, the latest close on NYSE showed EPAM at approximately $95 per share. Recent Reuters pricing data confirms EPAM’s NYSE listing and trading range.

EPAM InfoNgen information-intelligence platform in brief

• Product: InfoNgen research-intelligence platform
• Manufacturer: EPAM Systems, Inc.
• Category: Software-as-a-service / information intelligence
• Launch date: Initially launched in the late 2000s, with ongoing updates as part of EPAM’s information-intelligence offerings
• MSRP / Price: Subscription pricing, typically enterprise contracts tailored to content sources and user counts (commercial terms not publicly listed)
• Availability: Offered directly by EPAM to institutional clients in financial services, life sciences and other research-intensive industries worldwide
• Target audience: Research analysts, knowledge-management teams, compliance and risk officers in banks, asset managers, pharmaceutical companies and large corporates
• Key differentiator / USP: Combines machine learning and rule-based text analytics to unify external and internal unstructured content into a single, searchable, alert-driven research environment

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.